A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Clinical trial NCT06890884 · RECRUITING
Trial details
- NCT number
- NCT06890884
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-11
- Primary completion
- 2027-12-13
- Enrollment
- 594
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.